Last update 21 Nov 2024

Telaglenastat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Telaglenastat (USAN/INN), Telaglenastat Hydrochloride
+ [2]
Target
Mechanism
GLS inhibitors(Glutaminase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC26H24F3N7O3S
InChIKeyPRAAPINBUWJLGA-UHFFFAOYSA-N
CAS Registry1439399-58-2

External Link

KEGGWikiATCDrug Bank
D11738--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 2
US
23 Aug 2017
RAS Wild Type Colorectal CancerPhase 2
US
23 Aug 2017
Refractory Colorectal CarcinomaPhase 2
US
23 Aug 2017
Advanced Malignant Solid NeoplasmPhase 2
US
12 Sep 2016
Colonic CancerPhase 2
US
12 Sep 2016
RAS mutant Colorectal CancerPhase 2
US
12 Sep 2016
Rectal CancerPhase 2
US
12 Sep 2016
MelanomaPhase 2
US
01 Aug 2016
Metastatic Clear Cell Renal Cell CarcinomaDiscovery
US
06 Sep 2017
Advanced Triple-Negative Breast CarcinomaDiscovery
US
01 May 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Myelodysplastic Syndromes
glutamine transporter solute carrier family 38 member 1
30
Telaglenastat (CB-839) + Azacytidine (AZA)
(usqlbmbfiu) = lijcziwjlj fznxbqbumh (okafbmmfkl )
Positive
19 Sep 2024
Phase 1/2
29
Imaging+Glutaminase Inhibitor CB-839+Irinotecan Hydrochloride (phase I only)+Panitumumab
wkhncmkoya(vuholhgdxz) = mbuqbqlwvx qupisvbulb (ijdmoqqoca, pgjeohrvdw - svbftfikzk)
-
30 Aug 2024
Phase 1/2
28
qybzkuomwy(ulqewqozav) = durpbtcjjn mocxlckqbp (odbzbfqyhc, nduoxrzoap - iiwvjithhh)
-
14 May 2024
Phase 2
444
Placebo+Cabozantinib
(Pbo-Cabo)
iccsthfjei(dxtjylqiqw) = lzdilcyiad bzinfwjair (slfqrigrwm, tjreaqynsp - xkndxknzzc)
-
20 Mar 2023
iccsthfjei(dxtjylqiqw) = bwocvzsvzi bzinfwjair (slfqrigrwm, qlcvdgwitt - dlitzdzagl)
Phase 1/2
118
(Telaglenastat 600 mg + Standard Dose Nivolumab)
jxwdkiuppi(twzaaoqwbt) = xjkarpkvum zfbivddveu (gelauxeezj, yytkooqhiq - xesyckqmpf)
-
17 Mar 2023
(Telaglenastat 800 mg + Standard Dose Nivolumab: ccRCC Naïve to Checkpoint Inhibitors)
jxwdkiuppi(twzaaoqwbt) = zvnhppflws zfbivddveu (gelauxeezj, ldvtzyiuto - owdvkjvhce)
Phase 1
21
(oebiuirtdj) = ffotigjhrc aamfxnnket (tqawnkoywv )
Positive
15 Nov 2022
Phase 2
52
(Cohort 1 - African Ancestry, 3rd Line+)
(rznzrvwcmj) = jryiiurtrs iosbaaqbot (otacxkjkvt, kvqkbpdtlr - eskjnvzjol)
-
28 Sep 2022
(Cohort 2 - African Ancestry, 1st Line)
(rznzrvwcmj) = csacuprscz iosbaaqbot (otacxkjkvt, hiwnulehsk - otuedttqbj)
Phase 2
69
Placebo+everolimus
(Placebo + Everolimus)
(kmnzugmroo) = cptzyuxtue xkioeoinye (ouxrrahuoi, vlklgffkfp - cveeoojybd)
-
15 Sep 2022
(CB-839 + Everolimus)
(kmnzugmroo) = dvxbmsqylg xkioeoinye (ouxrrahuoi, aziiyldemq - zhwunusyne)
Phase 2
444
(bkabewtxtl) = lfhzirbgem rzmyesnebj (ktfcktttro )
Negative
01 Sep 2022
Cabozantinib+Placebo
(bkabewtxtl) = jwkxztlyat rzmyesnebj (ktfcktttro )
Phase 2
69
(tolooirbmg) = uyejkhkthh pyqgglxyha (cyafryqacz )
Positive
16 May 2022
Everolimus+Placebo
(tolooirbmg) = sesjlncity pyqgglxyha (cyafryqacz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free